Oncothyreon (NASDAQ: [[ticker:ONTY]]), the Seattle-based developer of cancer drugs, said today it has raised $14.9 million through a private placement transaction. The company sold 4.24 million securities units (a combination of common stock and warrants) at $3.50 apiece. That represents a 7.2 percent discount to the 30-day trailing average stock price, Oncothyreon said. JMP Securities led the deal, and Roth Capital Partners served as the co-agent.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
